Sutilain

Identification

Generic Name
Sutilain
DrugBank Accession Number
DB09379
Background

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity.2 Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.3

Type
Biotech
Groups
Approved, Withdrawn
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Sutilaina
  • Sutilaines
  • Sutilains
External IDs
  • BAX 1515
  • BAX-1515

Pharmacology

Indication

Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.2

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner.1 When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat.4

Mechanism of action

Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase.[T170]

Absorption

Sutilain is not absorbed.

Volume of distribution

This pharmacokinetic parameter is not relevant.

Protein binding

This pharmacokinetic parameter is not relevant.

Metabolism

This pharmacokinetic parameter is not relevant.

Route of elimination

This pharmacokinetic parameter is not relevant.

Half-life

This pharmacokinetic parameter is not relevant.

Clearance

This pharmacokinetic parameter is not relevant.

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

The toxicity has not been determined.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Travase Ointment 82000 Casein Units/gmOintment82000 unit / gTopicalBoots Pharmaceuticals Ltd.1987-12-311996-09-09Canada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
2PU6O23V1G
CAS number
12211-28-8

References

General References
  1. Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6. [Article]
  2. Kokate C., Purohit A. and Gokhale S. (2008). Pharmacognosy (42nd ed.). Pragati Book House. [ISBN:978-81-96396-15-2]
  3. FDA approval [Link]
  4. US Army Annual progress report [Link]
PubChem Substance
347910450
RxNav
227410

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
OintmentTopical82000 unit / g
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on November 30, 2015 19:10 / Updated on June 12, 2020 16:52